Shares of Roche Holding AG (OTCMKTS:RHHVF) have received a consensus rating of “Hold” from the nine ratings firms that are covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and four have issued a buy rating on the company.
RHHVF has been the topic of several recent analyst reports. Sanford C. Bernstein restated a “buy” rating on shares of Roche in a research note on Wednesday, April 21st. JPMorgan Chase & Co. restated a “hold” rating on shares of Roche in a research note on Monday, July 5th. Barclays restated a “buy” rating on shares of Roche in a research note on Wednesday, April 21st. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Roche in a research note on Friday, June 25th.
OTCMKTS:RHHVF traded up $2.66 during trading hours on Friday, hitting $386.50. 1,825 shares of the company traded hands, compared to its average volume of 6,171. The business’s 50-day simple moving average is $365.49. Roche has a one year low of $308.57 and a one year high of $390.01.
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation.
Recommended Story: Environmental, Social, and Governance (ESG) Investing
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.